Akebia Therapeutics (AKBA) Misses Q1 EPS by 22c, Revenues Miss

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/27/2026

1. ORCL
2. AVGO
3. CDNS
4. ANT
5. META
6. SPY
7. INTC
8. JBLU
9. BA
10. HOOD

Go back to Akebia Therapeutics (AKBA) Misses Q1 EPS by 22c, Revenues Miss

Akebia Therapeutics Reports First Quarter 2019 Financial Results; Announces Full Enrollment of Phase 3 INNO2VATE Studies and Announces Key Executive Appointments

May 9, 2019 8:00 AM EDT

Net Product Revenue for Auryxia Increases to $23.1 Million for Q1FY19, Up 12.1% from Q1FY18; Full Enrollment of Phase 3 INNO2VATE Studies; and Additions to Executive Leadership Team to Support Commercial and Clinical Operations.

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a... More